Kexing Biopharm has entered into a strategic partnership with IQVIA, a provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries.
The partnership aims to accelerate the global clinical development, regulatory approval, and commercialization of Kexing’s innovative drugs and biosimilars, with a strategic focus on Europe and other regulated international markets.
In recent years, Kexing Biopharm has taken steps toward internationalisation by building a platform that integrates advanced R&D capabilities with commercial execution. The company has facilitated the overseas market entry of several high-quality pharmaceutical products. Its in-licensed nab-paclitaxel has already achieved rapid approval and launch in several key jurisdictions.
Meanwhile, the company is advancing its R&D pipeline, focusing on therapeutic areas such as antivirus, antitumour, immunosuppressant, and metabolic diseases.
The partnership leverages IQVIA’s work in global clinical trial design, regulatory strategy, and data-driven insights. By combining Kexing’s product pipeline with IQVIA’s global operational infrastructure, the two companies aim to enhance trial efficiency, and enable faster access to international markets.
The collaboration is expected to significantly strengthen Kexing’s global development capabilities and accelerate its transition toward becoming an international biopharmaceutical innovator.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
